Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model

Molecular Therapy

Volumn 21, Issue 8, 2013, Pages 1602-1610

  Krakora, Dan ^a   Mulcrone, Patrick ^a   Meyer, Michael ^a   Lewis, Christina ^a   Bernau, Ksenija ^a   Gowing, Genevieve ^b,e   Zimprich, Chad ^c   Aebischer, Patrick ^d   Svendsen, Clive N ^b,e   Suzuki, Masatoshi ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c PROMEGA CORPORATION   (United States)

^d EPFL   (Switzerland)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIATERMIN; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RECOMBINANT SOMATOMEDIN C; RECOMBINANT VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ENGINEERING; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EX VIVO GENE TRANSFER; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; LIFE EXTENSION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOTONEURON; MOTOR DYSFUNCTION; NEUROMUSCULAR SYNAPSE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; STEM CELL GENE THERAPY; SURVIVAL TIME;

RATTUS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; LONGEVITY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MOTOR NEURONS; MUSCLE, SKELETAL; NEUROMUSCULAR JUNCTION; RATS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84881313291     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.108     Document Type: Article

References (50)

1. Boillée, S, Vande Velde, C and Cleveland, DW (2006). ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron 52: 39-59.
2. Wijesekera, LC and Leigh, PN (2009). Amyotrophic lateral sclerosis. Orphanet J Rare Dis 4: 3.
3. Kiernan, MC, Vucic, S, Cheah, BC, Turner, MR, Eisen, A, Hardiman, O et al. (2011). Amyotrophic lateral sclerosis. Lancet 377: 942-955.
4. Rosen, DR, Siddique, T, Patterson, D, Figlewicz, DA, Sapp, P, Hentati, A et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62.
5. Siddique, T and Ajroud-Driss, S (2011). Familial amyotrophic lateral sclerosis, a historical perspective. Acta Myol 30: 117-120.
6. Ticozzi, N, Tiloca, C, Morelli, C, Colombrita, C, Poletti, B, Doretti, A et al. (2011). Genetics of familial Amyotrophic lateral sclerosis. Arch Ital Biol 149: 65-82.
7. Gurney, ME (1994). Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 331: 1721-1722.
8. Howland, DS, Liu, J, She, Y, Goad, B, Maragakis, NJ, Kim, B et al. (2002). Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 99: 1604-1609.
9. Herbik, MA, Chrapusta, SJ, Kowalczyk, A and Grieb, P (2006). Maintenance of the rat transgenic model of familial amyotrophic lateral sclerosis expressing human SOD1G93A mutation. Folia Neuropathol 44: 149-153.
10. Julien, JP (2001). Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 104: 581-591.
11. Ilieva, H, Polymenidou, M and Cleveland, DW (2009). Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 187: 761-772.
12. Ferraiuolo, L, Kirby, J, Grierson, AJ, Sendtner, M and Shaw, PJ (2011). Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 7: 616-630.
13. Fischer, LR, Culver, DG, Tennant, P, Davis, AA, Wang, M, Castellano-Sanchez, A et al. (2004). Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp Neurol 185: 232-240.
14. Krakora, D, Macrander, C and Suzuki, M (2012). Neuromuscular junction protection for the potential treatment of amyotrophic lateral sclerosis. Neurol Res Int 2012: 379657.
15. Apfel, SC (2001). Neurotrophic factor therapy-prospects and problems. Clin Chem Lab Med 39: 351-355.
16. Suzuki, M and Svendsen, CN (2008). Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci 31: 192-198.
17. Henderson, CE, Phillips, HS, Pollock, RA, Davies, AM, Lemeulle, C, Armanini, M et al. (1994). GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266: 1062-1064.
18. Mohajeri, MH, Figlewicz, DA and Bohn, MC (1999). Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum Gene Ther 10: 1853-1866.
19. Wang, LJ, Lu, YY, Muramatsu, S, Ikeguchi, K, Fujimoto, K, Okada, T et al. (2002). Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 22: 6920-6928.
20. Acsadi, G, Anguelov, RA, Yang, H, Toth, G, Thomas, R, Jani, A et al. (2002). Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum Gene Ther 13: 1047-1059.
21. Suzuki, M, McHugh, J, Tork, C, Shelley, B, Klein, SM, Aebischer, P et al. (2007). GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE 2: E689.
22. Suzuki, M, McHugh, J, Tork, C, Shelley, B, Hayes, A, Bellantuono, I et al. (2008). Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther 16: 2002-2010.
23. Kaspar, BK, Lladó, J, Sherkat, N, Rothstein, JD and Gage, FH (2003). Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839-842.
24. Kaspar, BK, Frost, LM, Christian, L, Umapathi, P and Gage, FH (2005). Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis. Ann Neurol 57: 649-655.
25. Azzouz, M, Ralph, GS, Storkebaum, E, Walmsley, LE, Mitrophanous, KA, Kingsman, SM et al. (2004). VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429: 413-417.
26. Zheng, C, Nennesmo, I, Fadeel, B and Henter, JI (2004). Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol 56: 564-567.
27. Storkebaum, E, Lambrechts, D, Dewerchin, M, Moreno-Murciano, MP, Appelmans, S, Oh, H et al. (2005). Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8: 85-92.
28. Kliem, MA, Heeke, BL, Franz, CK, Radovitskiy, I, Raore, B, Barrow, E et al. (2011). Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGFZFP-TF) improves functional outcomes in SOD1 rats. Amyotroph Lateral Scler 12: 331-339.
29. Tsuzaka, K, Ishiyama, T, Pioro, EP and Mitsumoto, H (2001). Role of brain-derived neurotrophic factor in wobbler mouse motor neuron disease. Muscle Nerve 24: 474-480.
30. Campagnoli, C, Roberts, IA, Kumar, S, Bennett, PR, Bellantuono, I and Fisk, NM (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 98: 2396-2402.
31. Akiyama, C, Kobayashi, S and Nonaka, I (1992). Comparison of behavior in muscle fiber regeneration after bupivacaine hydrochloride- and acid anhydride-induced myonecrosis. Acta Neuropathol 83: 584-589.
32. Hill, M, Wernig, A and Goldspink, G (2003). Muscle satellite (stem) cell activation during local tissue injury and repair. J Anat 203 (1): 89-99.
33. Basso, DM, Beattie, MS and Bresnahan, JC (1995). A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12: 1-21.
34. Crisan, M, Yap, S, Casteilla, L, Chen, CW, Corselli, M, Park, TS et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3: 301-313.
35. LaBarge, MA and Blau, HM (2002). Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 111: 589-601.
36. Picinich, SC, Mishra, PJ, Mishra, PJ, Glod, J and Banerjee, D (2007). The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy. Expert Opin Biol Ther 7: 965-973.
37. Dodge, JC, Treleaven, CM, Fidler, JA, Hester, M, Haidet, A, Handy, C et al. (2010). AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther 18: 2075-2084.
38. Ferrara, N (2004). Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25: 581-611.
39. Airaksinen, MS and Saarma, M (2002). The GDNF family: Signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383-394.
40. Tufro, A, Teichman, J, Banu, N and Villegas, G (2007). Crosstalk between VEGF-A/VEGFR2 and GDNF/RET signaling pathways. Biochem Biophys Res Commun 358: 410-416.
41. Grounds, MD, White, JD, Rosenthal, N and Bogoyevitch, MA (2002). The role of stem cells in skeletal and cardiac muscle repair. J Histochem Cytochem 50 (5): 589-610.
42. Cossu, G and Mavilio, F (2000). Myogenic stem cells for the therapy of primary myopathies: Wishful thinking or therapeutic perspective? J Clin Invest 105: 1669-1674.
43. Pradat, PF, Barani, A, Wanschitz, J, Dubourg, O, Lombès, A, Bigot, A et al. (2011). Abnormalities of satellite cells function in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12: 264-271.
44. Li, W, Brakefield, D, Pan, Y, Hunter, D, Myckatyn, TM and Parsadanian, A (2007). Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93ASOD1 mouse model of ALS. Exp Neurol 203: 457-471.
45. Gowing, G and Svendsen, CN (2011). Stem cell transplantation for motor neuron disease: Current approaches and future perspectives. Neurotherapeutics 8: 591-606.
46. Boulis, NM, Federici, T, Glass, JD, Lunn, JS, Sakowski, SA and Feldman, EL (2011). Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol 8: 172-176.
47. Glass, JD, Boulis, NM, Johe, K, Rutkove, SB, Federici, T, Polak, M et al. (2012). Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: Results of a phase I trial in 12 patients. Stem Cells 30: 1144-1151.
48. Nichols, NL, Gowing, G, Satriotomo, I, Nashold, LJ, Dale, EA, Suzuki, M et al. (2013). Intermittent hypoxia and stem cell implants preserve breathing capacity in a rodent model of amyotrophic lateral sclerosis. Am J Respir Crit Care Med 187: 535-542.
49. Steer, JH, Mastaglia, FL, Papadimitriou, JM and Van, BI (1986). Bupivacaine-induced muscle injury. The role of extracellular calcium. J Neurol Sci 73 (2): 205-217.
50. Hayes-Punzo, A, Mulcrone, P, Meyer, M, McHugh, J, Svendsen, CN and Suzuki, M (2012). Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 13: 311-314.